SLC5A2 and chronic kidney disease: Although recent clinical trials have reported promising results with SGLT2 inhibition, most CKD patients still die prematurely or progress towards end-stage renal diseases (ESRD), needing kidney replacement therapies, such as dialysis or transplantation [1].